MAGEA1 and neoplasm: At tumour sites, 18 (75%), eight (33%), 11 (46%), five (21%), three (13%), and four (17%) patients had KK-LC-1, MAGE-A1, MAGE-A3, MAGE-A4, SSX4, and NY-ESO-1 expression.